IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. Hence, IL-5(Ra) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA). Therefore, several neutralizing monoclonal antibodies directed against IL-5 (mepolizumab and reslizumab) and its receptor IL-5Ra (benralizumab) have found or will find their way to the clinic. While the clinical effect of these drugs has been extensively investigated and reviewed, the understanding of the underlying immunological and hematological mechanisms remains less clear. This review will discuss the translational outcomes of treatment with these monoclonal antibodies in humans to shed light on the mechanisms underlying the main immunological and hematological findings from these clinical trials in humans.
| INTRODUCTION
Therapies targeted on the IL-5 pathway are a good extension in the treatment of patients with severe eosinophilic asthma.
1 This therapeutical approach has also shown promising results in the treatment of nasal polyps, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and other hypereosinophilic disorders. [2] [3] [4] For patients with severe eosinophilic asthma treatment with IL-5-targeting drugs result in a lower rate of exacerbations and a decrease in use of glucocorticoids. However, the quality of life and prebronchodilator FEV1 hardly improve in a clinically relevant way. 1, [5] [6] [7] [8] [9] [10] [11] [12] [13] In addition, only half of the patients with eosinophilic granulomatosis with polyangiitis reached a remission. 3 The lack of a complete clinical response in both diseases is difficult to understand as long as some important immunological and hematological issues of the therapy remain to be established. One of the key questions is whether eosinophils that remain in the body during IL-5-targeted therapy are an intrinsically different nonresponsive subset or residual "normal" cells, supporting the view that IL-5 is not critical in human eosinophilopoiesis. A third possibility is that residual eosinophils are found because of under dosing of the monoclonal antibodies such as recently suggested. 3, 14, 15 To gather
| THE FUNCTION OF INTERLEUKIN-5 IN

HOMEOSTASIS
| Receptor of IL-5 and its signal transduction
Interleukin-5 is a cytokine which is produced as a dimer and secreted by multiple cells such as Th2 cells, mast cells, ILC2 cells, and eosinophils. 16 It binds to the IL-5-specific a subunit-interleukin-5Ra (CD125)-that is part of a heterodimeric receptor with the common b subunit (CD131). This latter subunit is shared with the heterodimeric IL-3 receptor (CD123) and GM-CSF receptor (CD116). 17 The common b subunit does not express any ligand binding site but confers high-affinity ligand binding to intracellular signaling. 18 Upon binding of IL-5 to its receptor, juxtamembranous tyrosine kinases phosphorylate the bc receptor upon which at least 3 major signaling pathways are activated: JAK/STAT, MAPK, and PI-3K. 19 All 3 pathways eventually lead to rapid reprogramming of gene expression and a plethora of cellular responses ranging from proliferation of eosinophil progenitors to priming of cytotoxicity by mature cells. 20 Interestingly, IL-5 with a charge reversal mutation at position 12 (E12K) 21 and GM-CSF with a similar mutation at position 21 (E21R), 22 which are important for receptor binding, fail to stimulate tyrosine phosphorylation but can still affect survival. 21 This finding reveals the existence of 2 distinct mechanisms of receptor activation, one of which is a-chain specific.
| Expression of IL-5 receptors
In humans, the effects of IL-5 are restricted to basophils and eosinophils. 23 The expression of IL-5Ra on basophils is threefold lower compared to mature eosinophils and their differentiation is not dependent on this cytokine. 24 Therefore, the receptor is best characterized in the context of eosinophils. The receptor is both expressed on mature eosinophils and their progenitors including the eosinophil lineage-specific myeloblast (CD34 + and IL-5Ra + cells). 25 As stimulation of CD34 + /IL-5Ra + cells only produces eosinophils, it is yet not clear at what stage the IL-5Ra is upregulated on basophils. 25 In tissue, the level of IL-5Ra on eosinophils is lower compared to blood eosinophils. 26, 27 It seems plausible that the receptor is shed after migration to the tissue, because the amount of soluble IL-5Ra is increased in tissue. This hypothesis is supported by the finding that IL-5Ra is shed from the surface of healthy control eosinophils in vitro upon interaction with IL-5. This is probably due to proteolytic cleavage. 28 Whether IL-5Ra expression is also found on type 2 innate lymphoid cells (ILC2) is still a subject of debate, because the results in literature are inconsistent. in vitro, but unlike the other cytokines, IL-5 is the most eosinophil specific. 31, 32 The concentrations of IL-3 and GM-CSF in vitro need to be 10-fold higher in order to create eosinophils from marrow mononuclear cells instead of solely neutrophils or monocytes. 32 The formation of basophil colonies is also stimulated by IL-5 in HL-60 cells albeit to a lesser extent. 32, 33 In vivo, the situation is more complex. Murine experiments show a central role of IL-5 for reactive eosinophilia rather than differentiation per se, as IL-5 knockout mice do contain mature eosinophils in peripheral blood. They, however, do not exhibit eosinophilia after parasite infection. In culture systems of human CD34 + progenitor cells, IL-5 only induces transient proliferation and maturation of eosinophil precursors, which also suggests that IL-5 is a relatively lateacting factor for eosinophil proliferation rather than a factor for early differentiation. 34 All these experiments imply that other factors drive differentiation of eosinophil precursors and IL-5 is a major growth factor for IL-5R expressing cells, at least in mice. 34 
| The IL-5R and survival
In vitro the presence of IL-5 and GM-CSF increases mature eosinophil survival up to 10 days by inhibition of apoptosis. [35] [36] [37] The apoptotic eosinophils are normally recognized and phagocytosed by macrophages or to a lesser extent by small-airway epithelial cells in a process generally referred to as efferocytosis. 38, 39 In vivo the average circulatory lifespan of eosinophils was estimated to be between 11 and 63 hours. This large range is probably due to ex vivo manipulation of cells, 40 the use of toxic label, [40] [41] [42] and the difference in kinetics between homeostasis and pathological conditions. 43 The effect of IL-5 on these kinetics is unknown, but a clear negative correlation between eosinophil apoptosis and sputum IL-5 levels was found in asthmatic patients, which suggests that IL-5 is involved in inhibition of apoptosis in eosinophils in vivo. 44 48 The required doses are dependent on body weight and serum levels of IgE. As IgE is important in the Th2 allergic immune response, omalizumab is prescribed for patients with severe allergic asthma with high levels of aero-allergen specific IgE. 49 Both anti-IL-5 and anti-IgE target Th2-mediated inflammation and are therefore eligible for treating patients with eosinophilic and allergic asthma. A systematic review of available literature has shown that mepolizumab and omalizumab have similar therapeutic effects and tolerability in responsive patients with severe asthma. 50 As eosinophilic inflammation is not necessarily mediated through the "classical" IgE pathway, 51 anti-IL-5 seems to be favorable in all patients with signs of eosinophilic inflammation, but a direct clinical comparison has not been performed yet.
| KEY THERAPEUTIC E FFECTS OF IL-5 INHIBITION IN EOSIN OPHILIC-D RIVEN DISEASES
All asthma trials have in common that the effect of IL-5(R)-targeted therapy primarily leads to a decrease in disease exacerbations and steroid dependence rather than a direct effect on asthma characteristics such as changes in BHR and lung function. 1 For chronic rhinosinusitis with polyposis, both reslizumab and mepolizumab led to an improvement in symptoms for most, but not all patients. 52, 53 Besides this clinical effect, surgery was no longer required in 30% of patients treated with mepolizumab. 54 For eosinophilic esophagitis, anti-IL-5
did not lead to improvement of symptoms or histological remission. 55 Treating patients with hypereosinophilic syndrome (HES) with mepolizumab resulted in a lower dependence of prednisolone in less
Highlights
• IL-5 targeted therapy (mepolizumab or reslizumab) results in a clear attenuation of eosinophils in blood and a less distinct attenuation of eosinophils in (bronchial) tissue.
Basophils are attenuated in blood.
• Plasma and sputum IL-5 levels are increased after treatment. A possible source of elevated levels of IL-5 might be due to immune complexes between IL-5 and anti-IL-5.
• Early eosinophil progenitors (CD34 + and IL-5Ra + cells) might increase in blood and decrease in sputum after treatment.
HASSANI AND KOENDERMAN | 1981 than half of the patients. 4 Similarly, less than half of the eosinophilic granulomatosis and polyangiitis (EGPA) patients treated with mepolizumab reached complete remission. 3 Finally, in atopic dermatitis, mepolizumab did not lead to any clinical significant results, even though eosinophils may play a role in this disease. 56 
| INTERLEUKIN-5-TARGETED THERAPY: DIFFE RENCE BE TWEEN MICE AND MEN
There are key differences between murine and human data regarding pathogenesis of asthma and IL-5-targeted therapy. 23, [57] [58] [59] Therefore, this review focusses on human data rather than murine data.
| EFFECT OF ANTI-IL-5(R) ON EOSINOPHIL AND BASOPHIL NUMBERS IN PE RIPHERAL BLOOD AN D TISSUES
There has not been a study performed that directly compared mepolizumab and reslizumab in a randomized controlled clinical trial.
However, the results in the separate trials were comparable when it comes to reducing the number of circulating eosinophils (Table 1) . [5] [6] [7] [8] [9] [10] [11] Still, it was speculated that in a certain group of patients with steroid unresponsive asthma, the fixed lower concentration of mepolizumab (100 mg) might be insufficient to reduce the number of eosinophils in the tissues. It was even speculated based on preliminary studies that this low concentration might lead to formation of immune complexes between IL-5 and mepolizumab potentially activating tissue eosinophils. 14, 15 It was indeed found that lower concentrations of antibody were associated with lower reduction of both circulating and tissue eosinophils (Pavord et al 2012 Table 1 ). 6, 60 However, no data to date have directly measured the formation of immune complexes under these conditions and it remains to be established whether immune complexes are a worry in IL-5-targeted therapy.
Benralizumab depletes circulating eosinophils completely, likely through ADCC, although in some patients, small number circulatory cells still remained. 10, 12, 13, 61 However, the number of mucosal and/ or submucosal airway eosinophils was less affected by the treatment when compared to the effect on the number of circulating cells. 13, 62 It is too early to speculate how to interpret this counterintuitive finding, but the concept of the parallel presence of homeostatic and inflammatory eosinophils in the airways of eosinophilic asthmatics might shed some light on the tissue-dwelling cells in the future. 63 Next to altering eosinophil levels, 750 mg of mepolizumab also reduced the number of basophils in the tissue and bone marrow, although this reduction was less pronounced compared to eosinophils. 64 It is, therefore, likely that basophils rely on different cytokines such as IL-3.
65,66
The effect of mepolizumab on mast cells in tissue remains uncertain, because inconsistent results have been published. 24, 64, 67 Evidence that mast cells express the IL-5Ra receptor has only been provided in vitro in very limited number of studies.
68 Surprisingly, even though the expression of IL-5Ra is threefold lower on basophils, still a complete depletion of also basophils in peripheral blood is seen after treatment with benralizumab. 24, 62 This suggests that even though basophils rely on IL-3, a low membrane expression of IL-5Ra can already induce clearance through ADCC.
| IL-5 IS N OT ESSENTIAL FOR EOSIN OPHIL AN D BASOPHIL DIFFEREN TIATION AND PRODUCTION DURING H OME OSTASIS
It is now tempting to speculate why in response to all above-mentioned therapies a small amount of eosinophils can still be found in sputum or bronchial tissue in patients with asthma. 5, 6, 8, 13, 62 Also treatment of patients with eosinophilic esophagitis with 
| EFFECT OF ANTI-IL-5(RECEPTOR) MAB' S ON EOSINOPHIL PROGEN ITORS IN AND OUTSIDE THE BONE MARROW
Eosinophilopoiesis takes place in the bone marrow particularly under homeostasis. Under pathological conditions such as found in severe asthma, eosinophil progenitors (CD34 + and IL-5Ra-positive progenitors) have also been found in tissue and blood. This supports the hypothesis that extramedullary eosinophilopoiesis can take place. 71 In fact, in severe prednisolone-dependent asthma, the amount of eosinophil lineage-committed progenitor cells in sputum was over 700-fold higher compared to healthy controls, supporting a role of extramedullary hematopoiesis in eosinophil-driven disease. 72 In the bone marrow, mepolizumab (administered 750 mg intravenously) reduced both the mature and late immature eosinophils (myelocytes and metamyelocytes) significantly compared to placebo while the number of EoPs (early progenitors) was not attenuated in blood or bone marrow. 73 It can be hypothesized that IL-5 mainly influences eosinophil proliferation and maturation of relatively late progenitors rather than the reduction of early progenitors themselves. 73 However, the relative amount of late immature and mature eosinophils in the bone marrow was still high after 2 months of therapy (mean of 1.9% and 1.1%, respectively). This lack of complete depletion of relatively late progenitors might be due to a role of other cytokines, such as IL-3 and GM-CSF. 73 Indeed, treatment with GM-CSF also leads to eosinophilia. 74 Sehmi et al 72 showed an increase in blood levels of eosinophil lineage-committed progenitors compared to basal levels in patients who received 6 months of 100 mg mepolizumab by subcutaneous injection and not in patients who received placebo. This finding contradicts the fact that IL-5 can upregulate its own receptor on CD34 + cells, because a reduction rather than in increase in EoPs would be expected. 72, 75 Another finding of the same study was that the number of EoPs and mature eosinophils in sputum was not attenuated in these patients with severe asthma. The authors hypothesized that this might be due to insufficient bioavailability within the tissue of 100 mg mepolizumab opposed to 750 mg.
Indeed, in a comparable cohort of patients with severe asthma and prednisolone dependence, the same investigators showed that the number of early progenitors (EoPs) in blood was not attenuated by a low dose of mepolizumab in contrast to a weightadjusted relatively high dose of intravenous reslizumab. 14 The authors speculated that if also mepolizumab would have been administered high enough (weight-adjusted), the number of EoPs would in fact be diminished with a consequent attenuation of sputum eosinophils. This hypothesis is, however, contradicted by the finding of an earlier study in which unaltered levels of EoPs in blood and bone marrow were found after treatment with 750 mg mepolizumab. 73 In sputum, the amount of CD34 + /IL-5Ra + cells was also attenuated after treatment with 750 mg mepolizumab, but this was also seen with placebo. 73 In contrast to the findings obtained with anti-IL-5 antibodies, a complete depletion of eosinophils and their early progenitors in the bone marrow was seen in a very small cohort of 4 patient with asthma that were treated with a single dose of 1 mg/kg benralizumab (anti-IL-5Ra) via an intravenous injection. 62 It is possible that this difference in the amount of bone marrow eosinophils and late progenitors in comparison with mepolizumab is caused by antibodydependent cell-mediated cytotoxicity. 24 Similarly, EoPs are also strongly attenuated in blood and sputum after treatment with benralizumab. 61 
| EFFE CT OF AN TI-IL-5(RECEPTOR) ON CELLULAR PRIMING AND ACTIVATION
IL-5-targeted therapy also affects the release of eosinophil basic proteins in these compartments. For instance, it has been described that eosinophil cationic protein (ECP) is found in enhanced levels in serum of asthma patients. 76 Also increased concentrations of major basic protein (MBP), 77 eosinophil cationic protein (ECP), 78 and eosinophilic peroxidase (EPO) were found in tissue in this patient group. 70, 76 These cytotoxic proteins can affect extracellular matrix (ECM)proteins in the reticular basement membrane (EMB). 79 In addition, they can modulate TGF-b1 expression by airway eosinophils.
The concentrations of these mediators are blunted in BAL-fluid of patients with atopic asthma after treatment with mepolizumab. Treatment with anti-IL-5Ra antibodies (benralizumab) also caused a decreased concentration of ECP and eosinophil-derived neurotoxin (EDN) in serum, meaning that despite ADCC, no harmful proteins are released in blood. 82 All of the above suggest that anti-IL-5(Ra) not only attenuates eosinophil numbers but also reduces priming and/or activation of eosinophils and can therefore diminish inflammation and remodeling as well.
Despite these findings, the situation with priming and activation in vivo is more complex than these in vitro data suggest. This complexity is illustrated by the finding that the expression of activationassociated markers on eosinophils is not all pointing at complete suppression of eosinophil priming by IL-5(Ra)-targeted therapy. This is particularly shown by the expression of b 1 -integrin in their active configuration in blood eosinophils, which was not altered by treatment with mepolizumab. 80 Also, the amount of major basic protein (MBP) in tissue was not found to drop with reduction in eosinophils. 64 A possible explanation could be that the remaining eosinophils are still able to produce sufficient amounts of MBP or there is a different source of MBP-1. 83 Alternative tissue sources of MBP other than placenta are poorly defined although mRNA of the MBP gene (PRG1) has been found in multiple tissues. 84 Similarly, unexpected was the finding that the rise of bronchoalveolar eosinophils after an allergen challenge was strongly reduced after administration of 750 mg of mepolizumab intravenously, whereas the remaining eosinophils still showed an IL-5 signature (enhanced expression of CD23, CD44, and CD69). 70 
| EFFECT OF IL-5(Ra )-TARGE TED THERAPY ON IL-5 LEVE LS IN BLOOD AN D TISSUE
Treatment with anti-IL-5 (mepolizumab or reslizumab) eventually results in an increase in plasma levels of IL-5 (bound to Mab?) in patients with asthma, hypereosinophilic syndrome, and eosinophilic gastroenteritis even though there might be a slight decrease just after the start of treatment. 81, 85 This increase was also partially found in sputum of patients with asthma treated with mepolizumab but was surprisingly not seen in patients treated with reslizumab. unchanged. 92 This indicates that even within the spectrum of Th2-driven diseases, the pathogenesis of inflammation leading to tissue damage is complex. It is, therefore, not particularly surprising that single mediator antagonists only affect part of the disease spectrum in patients with complex immune-mediated diseases.
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